1 Min Read
* Otsuka and lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with Bipolar I disorder Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.